Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease
Identifieur interne : 001228 ( Istex/Checkpoint ); précédent : 001227; suivant : 001229Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease
Auteurs : Dan Caspi [États-Unis] ; Ori Elkayam [États-Unis] ; Miruna Eisinger [États-Unis] ; Nurit Vardinon [États-Unis] ; Michael Yaron [États-Unis] ; Michael Burke [États-Unis]Source :
- Rheumatology International [ 0172-8172 ] ; 2001-02-01.
English descriptors
- KwdEn :
Abstract
Abstract: The objective of this study was to evaluate the clinical significance of anti-nuclear antibodies (ANA) detected in the early stages of rheumatoid arthritis (RA), by a retrospective comparison of the clinical, laboratory, and therapeutic characteristics of patients with or without ANA. The files of 99 longstanding seropositive RA patients were reviewed. Data relating to demographics, medical history, family history, physical findings, extra-articular complications, laboratory tests, drugs [dosage, duration, efficacy, combinations, adverse effects (AEs)], intra-articular injections, and surgery were recorded. Patients with or without ANA at presentation of their disease were compared using chi-square and t-tests. Fifty-two ANA positive (group 1) and 47 ANA negative (group 2) patients were enrolled in the study. All were comparable in terms of their mean age, age at diagnosis, follow-up duration (∼10.5 years), and male:female (M:F) ratio. On admission, pain complaints were more pronounced in group 1 (P = 0.004 in the feet), but the physical findings did not differ. Deformities and nodules developed in similar numbers. Extra-articular complications were evenly distributed; vasculitis, however, was significantly more prevalent in ANA positive (10/52) than in ANA negative (2/47) patients. Thyroid disease was more common in group 2 (10/47 vs 3/52). Laboratory tests (presentation and maximal values) were similar, with the exception of higher anti-DNA (but within normal ranges) and γ-globulin% in group 1. Group 1 used more drugs prior to diagnosis. Corticosteroids and disease-modifying anti-rheumatic drugs (DMARDs) were evenly used. Combination therapy, joint injections, and surgery were more prevalent in group 2. AEs to various DMARDs were more common in group 1. Although similar in many aspects, RA patients with ANA tend to present with more pain complaints, a higher risk of vasculitis and AEs relating to use of DMARDs, while those without ANA needed more aggressive therapeutic modalities.
Url:
DOI: 10.1007/s002960000073
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:3426F98937024015B2BE35CDEE8B0AB81C99C24FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease</title>
<author><name sortKey="Caspi, Dan" sort="Caspi, Dan" uniqKey="Caspi D" first="Dan" last="Caspi">Dan Caspi</name>
</author>
<author><name sortKey="Elkayam, Ori" sort="Elkayam, Ori" uniqKey="Elkayam O" first="Ori" last="Elkayam">Ori Elkayam</name>
</author>
<author><name sortKey="Eisinger, Miruna" sort="Eisinger, Miruna" uniqKey="Eisinger M" first="Miruna" last="Eisinger">Miruna Eisinger</name>
</author>
<author><name sortKey="Vardinon, Nurit" sort="Vardinon, Nurit" uniqKey="Vardinon N" first="Nurit" last="Vardinon">Nurit Vardinon</name>
</author>
<author><name sortKey="Yaron, Michael" sort="Yaron, Michael" uniqKey="Yaron M" first="Michael" last="Yaron">Michael Yaron</name>
</author>
<author><name sortKey="Burke, Michael" sort="Burke, Michael" uniqKey="Burke M" first="Michael" last="Burke">Michael Burke</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3426F98937024015B2BE35CDEE8B0AB81C99C24F</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1007/s002960000073</idno>
<idno type="url">https://api.istex.fr/ark:/67375/VQC-KMBX0K4M-C/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001203</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001203</idno>
<idno type="wicri:Area/Istex/Curation">001203</idno>
<idno type="wicri:Area/Istex/Checkpoint">001228</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001228</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease</title>
<author><name sortKey="Caspi, Dan" sort="Caspi, Dan" uniqKey="Caspi D" first="Dan" last="Caspi">Dan Caspi</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Department of Rheumatology, Tel Aviv (Sourasky) Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel Fax: +972-3-6794577</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Elkayam, Ori" sort="Elkayam, Ori" uniqKey="Elkayam O" first="Ori" last="Elkayam">Ori Elkayam</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Department of Rheumatology, Tel Aviv (Sourasky) Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel Fax: +972-3-6794577</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Eisinger, Miruna" sort="Eisinger, Miruna" uniqKey="Eisinger M" first="Miruna" last="Eisinger">Miruna Eisinger</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Department of Rheumatology, Tel Aviv (Sourasky) Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel Fax: +972-3-6794577</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Vardinon, Nurit" sort="Vardinon, Nurit" uniqKey="Vardinon N" first="Nurit" last="Vardinon">Nurit Vardinon</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Department of Clinical Immunology, Tel Aviv (Sourasky) Medical Center, Tel Aviv, Israel</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Yaron, Michael" sort="Yaron, Michael" uniqKey="Yaron M" first="Michael" last="Yaron">Michael Yaron</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Department of Rheumatology, Tel Aviv (Sourasky) Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel Fax: +972-3-6794577</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Burke, Michael" sort="Burke, Michael" uniqKey="Burke M" first="Michael" last="Burke">Michael Burke</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Department of Clinical Immunology, Tel Aviv (Sourasky) Medical Center, Tel Aviv, Israel</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Rheumatology International</title>
<title level="j" type="sub">Clinical and Experimental Investigations</title>
<title level="j" type="abbrev">Rheumatology International</title>
<idno type="ISSN">0172-8172</idno>
<idno type="eISSN">1437-160X</idno>
<imprint><publisher>Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<date type="published" when="2001-02-01">2001-02-01</date>
<biblScope unit="volume">20</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="43">43</biblScope>
<biblScope unit="page" to="47">47</biblScope>
</imprint>
<idno type="ISSN">0172-8172</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0172-8172</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-nuclear antibodies</term>
<term>Disease-modifying anti-rheumatic drugs</term>
<term>Key words Rheumatoid arthritis</term>
<term>Laboratory tests</term>
<term>Vasculitis</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: The objective of this study was to evaluate the clinical significance of anti-nuclear antibodies (ANA) detected in the early stages of rheumatoid arthritis (RA), by a retrospective comparison of the clinical, laboratory, and therapeutic characteristics of patients with or without ANA. The files of 99 longstanding seropositive RA patients were reviewed. Data relating to demographics, medical history, family history, physical findings, extra-articular complications, laboratory tests, drugs [dosage, duration, efficacy, combinations, adverse effects (AEs)], intra-articular injections, and surgery were recorded. Patients with or without ANA at presentation of their disease were compared using chi-square and t-tests. Fifty-two ANA positive (group 1) and 47 ANA negative (group 2) patients were enrolled in the study. All were comparable in terms of their mean age, age at diagnosis, follow-up duration (∼10.5 years), and male:female (M:F) ratio. On admission, pain complaints were more pronounced in group 1 (P = 0.004 in the feet), but the physical findings did not differ. Deformities and nodules developed in similar numbers. Extra-articular complications were evenly distributed; vasculitis, however, was significantly more prevalent in ANA positive (10/52) than in ANA negative (2/47) patients. Thyroid disease was more common in group 2 (10/47 vs 3/52). Laboratory tests (presentation and maximal values) were similar, with the exception of higher anti-DNA (but within normal ranges) and γ-globulin% in group 1. Group 1 used more drugs prior to diagnosis. Corticosteroids and disease-modifying anti-rheumatic drugs (DMARDs) were evenly used. Combination therapy, joint injections, and surgery were more prevalent in group 2. AEs to various DMARDs were more common in group 1. Although similar in many aspects, RA patients with ANA tend to present with more pain complaints, a higher risk of vasculitis and AEs relating to use of DMARDs, while those without ANA needed more aggressive therapeutic modalities.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Illinois</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Illinois"><name sortKey="Caspi, Dan" sort="Caspi, Dan" uniqKey="Caspi D" first="Dan" last="Caspi">Dan Caspi</name>
</region>
<name sortKey="Burke, Michael" sort="Burke, Michael" uniqKey="Burke M" first="Michael" last="Burke">Michael Burke</name>
<name sortKey="Eisinger, Miruna" sort="Eisinger, Miruna" uniqKey="Eisinger M" first="Miruna" last="Eisinger">Miruna Eisinger</name>
<name sortKey="Elkayam, Ori" sort="Elkayam, Ori" uniqKey="Elkayam O" first="Ori" last="Elkayam">Ori Elkayam</name>
<name sortKey="Vardinon, Nurit" sort="Vardinon, Nurit" uniqKey="Vardinon N" first="Nurit" last="Vardinon">Nurit Vardinon</name>
<name sortKey="Yaron, Michael" sort="Yaron, Michael" uniqKey="Yaron M" first="Michael" last="Yaron">Michael Yaron</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001228 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 001228 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Istex |étape= Checkpoint |type= RBID |clé= ISTEX:3426F98937024015B2BE35CDEE8B0AB81C99C24F |texte= Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease }}
This area was generated with Dilib version V0.6.33. |